Last reviewed · How we verify
Aformoterol
At a glance
| Generic name | Aformoterol |
|---|---|
| Also known as | Brovana |
| Sponsor | University of Massachusetts, Worcester |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI (NA)
- Asthma Exacerbation and Helium-3 MRI (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aformoterol CI brief — competitive landscape report
- Aformoterol updates RSS · CI watch RSS
- University of Massachusetts, Worcester portfolio CI